Heroin

DGAP-News: Virpax(R) Pharmaceuticals Inc.: Virpax Begins IND Enabling Studies of Envelta(TM)

Tuesday, February 23, 2021 - 1:11pm

Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic.

Key Points: 
  • Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic.
  • Dr. Jeffrey Gudin, principal investigator and co-founder of Virpax, has been working in partnership with the NCATS since we announced the CRADA in August 2020.
  • Envelta(TM) is an intranasal enkephalin drug product candidate formulation based on nanotechnology which enables the delivery of the drug product to the brain.
  • Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery.

$2+ Billion Worldwide Opiod Induced Constipation Drugs Industry to 2028 - Key Drivers, Challenges and Opportunities

Tuesday, February 23, 2021 - 11:45am

In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid induced constipation.

Key Points: 
  • In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid induced constipation.
  • The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better market understanding of the overall opioid induced constipation drugs market.
  • Key questions answered in this report:
    What are the current market trends and dynamics in the opioid induced constipation drugs market and valuable opportunities for emerging players?
  • Notable developments going on in the opioid induced constipation drugs market.

NJ Patient Notification Law Introduced by Congress to Help Prevent Opioid Addiction Nationally

Monday, February 22, 2021 - 8:04pm

), has introduced the bipartisanOpioid Patients' Right to Know Actto help prevent opioid addiction across the country that is based on the success of the New Jersey Patient Notification Act .

Key Points: 
  • ), has introduced the bipartisanOpioid Patients' Right to Know Actto help prevent opioid addiction across the country that is based on the success of the New Jersey Patient Notification Act .
  • "The Opioid Patients' Right to Know Act provides a proven prevention measure, and I urge Congress to move speedily to adopt it."
  • "It is much easier to prevent opioid use disorder in the first place than it is to treat it.
  • "I am proud that what we have done in New Jersey to prevent opioid dependency and addiction can serve as a model for the country," he said.

Worldwide Syringe Industry to 2027 - Expanding Injectables Market Presents Opportunities

Friday, February 19, 2021 - 12:00pm

According to this report the global syringe market is expected to reach $26,859.34 million by 2027 from $12,649.46 million in 2019.

Key Points: 
  • According to this report the global syringe market is expected to reach $26,859.34 million by 2027 from $12,649.46 million in 2019.
  • The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
  • Based on syringe type, the market is segmented into luer lock syringes, glass syringes, luer slip syringes, and others.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Global Opiod Induced Constipation Drugs Market (2020 to 2028) - Players Include AstraZeneca, Cubist Pharmaceuticals and Daiichi Sankyo Among Others - ResearchAndMarkets.com

Thursday, February 18, 2021 - 5:13pm

The "Opiod Induced Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Opiod Induced Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global opioid induced constipation drugs market is rising at a significant pace, projected to rise at a CAGR of 4.7% during the estimated period from 2020 to 2028, starting from US$ 2,656.4 Mn in 2019.
  • In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid induced constipation.
  • In addition, irrational intake of OTC drugs and lack of physical activity will further aggravate the occurrence of opioid induced constipation in the elderly population

An analysis of drugs in used syringes from sentinel European cities: results from the ESCAPE project, 2018 and 2019

Thursday, February 18, 2021 - 12:05am

An analysis of drugs in used syringes from sentinel European cities: results from the ESCAPE project, 2018 and 2019

Key Points: 
  • An analysis of drugs in used syringes from sentinel European cities: results from the ESCAPE project, 2018 and 2019
    This report presents new findings from the ESCAPE (European Syringe Collection and Analysis Project Enterprise) network, based on the chemical analysis of the contents of used syringes across sentinel sites in Europe.
  • Syringes were collected in 2018 and 2019 from the bins of street automatic injection-kit dispensers and at harm reduction services in eight European cities: Amsterdam, Budapest, Cologne, Helsinki, Lausanne, Oslo, Paris and Vilnius.

European Syringe Collection and Analysis Enterprise (ESCAPE) – generic protocol

Thursday, February 18, 2021 - 12:05am

This protocol documents a new approach that has been developed to monitor substances injected by people who inject drugs through analytically confirmed data at the local level: the analysis of residual content of used syringes.

Key Points: 
  • This protocol documents a new approach that has been developed to monitor substances injected by people who inject drugs through analytically confirmed data at the local level: the analysis of residual content of used syringes.
  • Used syringes contain traces of drugs that can be analysed to inform public health professionals about injecting drug use, and to contribute to the understanding of drug addiction among people who inject drugs.
  • Used syringes can be collected from low-threshold services where needle exchange programmes are in place.
  • They can also be collected from automatic injection kit dispensers, combined with street bins (where people who inject drugs can obtain their new sterile injection kit in return of a used syringe), thereby obtaining injecting material from populations that might not be in contact with health and social services.

Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate

Wednesday, February 17, 2021 - 2:00pm

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHIhigh dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.

Key Points: 
  • SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHIhigh dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.
  • The company believes this patent should protect and strengthen the existing intellectual property associated with the product candidate.
  • Concomitant with the rise of overdoses caused by synthetic opioids, deaths have risen despite increased availability of the current naloxone product.
  • Adamis naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review.

An open letter from Darryl Tempest – Executive Director of the Canadian Vaping Association

Tuesday, February 16, 2021 - 4:09pm

The government responded by creating safe injection sites and are now considering decriminalizing heroine, fentanyl and cocaine.

Key Points: 
  • The government responded by creating safe injection sites and are now considering decriminalizing heroine, fentanyl and cocaine.
  • These measures were designed to provide safe spaces for addicts and to connect them with needed resources.
  • In large part, the confusion surrounding vaping stems from legitimate concerns regarding increased youth vaping rates.
  • These campaigns are contrary to the fact that vaping is the most successful tool in history to address smoking rates.

Global Syringe Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Tuesday, February 16, 2021 - 4:00pm

The "Syringe Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Syringe Type, Application, Usability, and End User and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Syringe Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Syringe Type, Application, Usability, and End User and Geography" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the global syringe market is expected to reach $26,859.34 million by 2027 from $12,649.46 million in 2019.
  • Based on syringe type, the market is segmented into luer lock syringes, glass syringes, luer slip syringes, and others.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.